A Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease, in partnership with the World Heart Federation, European Society of Cardiology, Inter American Society of Cardiology, Pan-African Society of Cardiology, Asian Pacific Society of Cardiology, European Atherosclerosis Society, International Atherosclerosis Society.
The overall objective of INTERASPIRE is to describe the management of cardiovascular risk factors, and current use of cardioprotective medications, in relation to international and national guideline standards on prevention of cardiovascular disease. Find out more here
INTERASPIRE Lp(a) Sub Study
A Lp(a) sub-study of secondary prevention in atherosclerotic cardiovascular disease and patients’ and physicians’ knowledge and attitudes towards measuring and managing Lp(a)
The Lp(a) sub-study will be conducted in seven selected INTERASPIRE countries from all six WHO regions in 2022–2024, recruiting 960 patients and 210 physicians. This sub-study is an exciting opportunity to explore a new risk marker for cardiovascular disease in the context of an international epidemiological study which will yield important new scientific data on measuring and managing Lp(a). Find out more here